<DOC>
	<DOCNO>NCT00586612</DOCNO>
	<brief_summary>The purpose Phase IIIb study evaluate immunogenicity , reactogenicity &amp; safety GSK Biologicals ' Hib-MenC vaccine ( Menitorix™ ) co-administered GSK Biologicals ' DTPa-HBV-IPV vaccine ( Infanrix™ penta ) &amp; Wyeth 's 7-valent pneumococcal conjugate vaccine ( Prevenar™ ) preterm infant 3-dose primary vaccination course first 6 month life ( 2 , 4 , 6 month age ) booster dose Menitorix™ co-administered GSK Biologicals ' DTPa-IPV vaccine ( Infanrix IPV ) Wyeth 's Prevenar second year life ( 16-18 month age ) . The control group full-term infant receive vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Primary &amp; Booster Study Evaluate Immunogenicity Safety Menitorix Vaccine Preterm Infants</brief_title>
	<detailed_description>This multicenter study open &amp; consist primary &amp; booster phase . The study 2 treatment group ( Preterm &amp; Full-term ) receive vaccination ; Full-term group active control . Four blood sample collect subject immunogenicity analyse ; 2 primary phase prior first vaccination one month third vaccination 2 booster phase prior booster dose one month booster dose .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 8 12 week age time first vaccination . Written inform consent obtain parent guardian subject . All preterm subject must satisfy follow criterion study entry : Born gestation period less equal 36 week ( ≤258 day ) . Medically stable , i.e . require significant medical support ongoing management debilitate disease demonstrate clinical course sustain recovery . All fullterm subject must satisfy follow criterion study entry : Born gestation period include 37 42 week ( ≥259 day ≤294 day ) . Free obvious health problem establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Planned administration/ administration vaccine foreseen study protocol period start 30 day first dose vaccine last study visit , except measlesmumpsrubella ( MMR ) varicella vaccine may give accord local immunisation practice except rotavirus oral vaccine allow anytime study hospital discharge per prescribe information . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , meningococcal serogroup C Streptococcus pneumoniae disease , exception hepatitis B vaccine BCG vaccine give first month life accord national recommendation ( although BCG hepatitis B vaccine give outside 30day window first administration study vaccine ) . History diphtheria , tetanus , pertussis , polio , hepatitis B , H. influenzae type b , meningococcal disease S. pneumoniae disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulin ( exception monoclonal antibody respiratory syncytial virus [ RSV ] ) and/or blood product within one month ( 30 day ) precede first dose study vaccine . Planned administration immunoglobulins and/or blood product active phase study . Specific criterion booster part study ( checked Visit 5 , study month 14 ) : History diphtheria , tetanus , pertussis , polio , hepatitis B , H. influenzae type b , meningococcal disease S. pneumoniae disease . Previous vaccination , except study vaccine hepatitis birth dose , diphtheria , tetanus , pertussis , polio , hepatitis B , H. influenzae type b , meningococcal disease S. pneumoniae disease . Previous booster vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , H. influenzae type b , meningococcal disease and/or S. pneumoniae disease .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Conjugate vaccine</keyword>
	<keyword>Persistence</keyword>
	<keyword>Hib vaccine</keyword>
	<keyword>Combination vaccine</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Safety</keyword>
	<keyword>Preterm/full-term infant</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>